IN/1616



PATENT Attorney Docket No. 056291-5192

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ANDERBERG et al.) Confirmation No.: 4755
Application No.: 10/520,939) Group Art Unit: 1645
Filed: January 12, 2005) Examiner: Unassigned
For: COMBINATION OF AN IBAT INHIBITOR AND A METAL SALT FOR THE TREATMENT OF DIARRHOEA)))

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Inventor	U.S. Serial No.	U.S. Patent No.	PCT Publication No.	
	Filing Date	Issue Date	PCT Publication Date	
Starke et al.	10/220,877	6,906,058	WO 01/66533	
	March 5, 2001	June 14, 2005	September 13, 2001	
Starke et al.	10/399,336		WO 02/32428	
	September 16, 2003		April 25, 2002	
Starke et al.	10/451,262		WO 02/50051	
	June 20, 2003		June 27, 2002	
Starke et al.	10/488,540		WO 03/020710	
	July 23, 2004		March 13, 2003	
Starke et al.	10/489,009		WO 03/022825	
	October 8, 2004		March 20, 2003	
Starke et al.	10/489,010		WO 03/022830	
	October 21, 2004		March 20, 2003	
Starke et al.	10/488,870		WO 03/022286	
	October 7, 2004		March 20, 2003	
Lindqvist	10/502,355		WO 03/061663	
	February 4, 2005		July 31, 2003	
Starke et al.	10/511,984		WO 03/091232	
	October 21, 2004		November 6, 2003	

Inventor		U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Starke et al.	10/518,010		WO 03/106482
	December 14, 2004		December 24, 2003

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Supplemental Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of a published U.S. Application, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

This submission does not represent that a search has been made or that no better art exists and

does not constitute an admission that each or all of the listed documents are material or constitute "prior

art." If it should be determined that the listed documents constitute "prior art" under United States law,

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate

status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the

disclosed invention over the listed documents, should one or more of the documents be applied against

the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by

this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bockins

Date:

December 30, 2005

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel. No.: 202-739-3000

By:

Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5320

Fax No.: (202) 739-3001

Attorney Docket No. Application No. INFORMATION DISCLOSURE CHATION 056291-5192 10/520,939 (Use several sheets if necessary) Applicants: ANDERBERG et al. DEC 3 0 2005 PTO Form 1449 Filing Date: January 12, 2005 Group Art Unit: 1645 PRADEMA U.S. PATENT DOCUMENTS Initial Document No. Date Class Sub-Class Filing Date US 2002/142054 10/3/2002 Marlett et al. 424 738 September 10, 2001 FOREIGN PATENT DOCUMENTS Document No. **Country** Class Sub-Class Translation 2. DE 19825804 12/16/1999 DE 3. EP 0372542 6/13/1990 EP 4. EP 0864582 9/16/1998 EP 5. GB 2,262,888 7/7/1993 GB WO 93/16055 6. 8/19/1993 WIPO 7. WO 94/18183 8/18/1994 WIPO 8. WO 94/18184 8/18/1994 WIPO 9. WO 96/05188 2/22/1996 WIPO 10. WO 96/08484 3/21/1996 WIPO 11. WO 96/16051 5/30/1996 **WIPO** 12. WO 97/33882 9/18/1997 WIPO 13. WO 98/38182 9/3/1998 WIPO 14. WO 98/40375 9/17/1998 WIPO WO 99/01149 15. 1/14/1999 WIPO WO 99/32478 16. 7/1/1999 WIPO WO 99/35135 17. 7/15/1999 **WIPO** 18. WO 99/64409 12/16/1999 WIPO 19. WO 99/64410 12/16/1999 WIPO 1/13/2000 20. WO 00/01687 WIPO 21. WO 00/38725 7/6/2000 WIPO 22. WO 00/38726 7/6/2000 WIPO 23. WO 00/38727 7/6/2000 WIPO 24. WO 00/38728 7/6/2000 WIPO WO 00/38729 25. 7/6/2000 **WIPO** 26. WO 00/47568 8/17/2000 **WIPO** 27. WO 00/61568 10/19/2000 **WIPO** 28. WO 00/62810 10/26/2000 WIPO 29. WO 01/60807 8/23/2001 WIPO 30. WO 01/66533 9/13/2001 WIPO 31. WO 01/68096 9/20/2001 WIPO 32. WO 01/68637 9/20/2001 **WIPO** 33. WO 02/08211 1/31/2002 **WIPO** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CHATEON		DE CETATION	Attorney Docket No. 056291-5192		Application No. 10/520,939			
IMPOR			WE SHAFOT	UJU271-J172		· · · · · · · · · · · · · · · · · · ·	10/340,737	
(Use several sheets if necessary) Applicants: ANDERBERG et al. DEC 3 0 2005								
		PTO Form 1449	\2 \8/	Filing Date: January 12, 2005		Group Art Unit: 1645		
ļ			TRADEMATE.	NT DACIMINATE				
Initial	T	Document No.	Date	NT DOCUMENTS Name	Class	Sub-Class	Filing Date	
Hillian	 	Document 140.	Date	Ivanic	. Class	Sub-Ciass	Filling Date	
•	†				+	+ -		
	† <u> </u>					1		
			FOREIGN PA	TENT DOCUMENTS				
		Document No.	Date	Country	Class	Sub-Class	Translation	
	34.	WO 02/32428	4/25/2002	WIPO				
	35.	WO 02/50051	6/27/2002	WIPO			1988	
	36.	WO 02/53548	7/11/2002	WIPO			Y (Abstract)	
	37.	WO 03/020710	3/13/2003	WIPO				
	38.	WO 03/022286	3/20/2003	WIPO				
	39.	WO 03/022825	3/20/2003	WIPO				
	40.	WO 03/022830	3/20/2003	WIPO				
	41.	WO 03/061663	7/31/2003	WIPO				
	42.	WO 03/091232 WO 03/106482	11/6/2003	WIPO				
	44.	WO 03/106482 WO 2004/006899	12/24/2003 1/22/2004	WIPO				
	44.	WO 2004/006899 WO 2004/076430	9/10/2004	WIPO WIPO	 			
	46.	WO 2004/070430 WO 2004/089350	10/21/2004	WIPO		 		
	1-70.	W O 2004/00/330	10/21/2007	WIFO	-	+		
	1					<u> </u>		
	47.	OTHER DO	OCUMENTS (Including	Author, Title, Date, Pe	ertinent Pa	ges, etc.)	Marke Separately	
		amorphous calcium phosphate" Journal of Lipid Research, 35(5): 741-748						
	48.	Higaki et al., (1998) "Inhibition of Ileal Na ⁺ /Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits" Ateriosclerosis, Thrombosis, and Vascular Biology 18(8): 1304-1311						
	49.	Ishibashi et al., (1993)	"Hypercholesterolemia i	in low density lipoprotein Clinical Investigation 92	n receptor k	nockout mice	and its reversal by	
	50.	Lewis et al (1995) "E	ffects of 2164IJ90 on ile	eal bile acid absorption an	2(2): 000-0: ad cerum ch	olecterol in re	ate and mice" Journal	
		of Lipid Research, 36(5): 1098-1105	at one acid accorption an	iu scium ch	olesieror in 12	118 and times Journal	
	51.			mia and atherosclerosis in	n anolipopre	otein E-defici	ient mice created by	
		homologous recombina	ation in ES cells" Cell 71	1(2):343-353	w whompart	J	ioni imoo oromica o,	
	52.	Schiller (2001) "The th	herapy of constipation" A	Alimentary Pharmacology	y and Thera	peutics 15(6)	: 749-763	
	53.	Schiller (2001) "The therapy of constipation" Alimentary Pharmacology and Therapeutics 15(6): 749-763 Sprong et al., (2002) "Dietary Calcium Phosphate Promotes Listeria monocytogenes Colonization and Translocation in Rats Fed Diets Containing Corn Oil but Not Milk Fat" J. Nutrition (US) 132(6): 1269-1274						
	54.	Van Tilburg et al., (1989) "Na+-dependent bile acid transport in the ileum: The balance between diarrhea and						
	55.	o) ()						
	 	188: 52-59						
						- 100		
Carringe			b. 0					
Examiner			Date Cons	idered				
Examiner	: Initia	il if reference considered	d, whether or not citation	is in conformance with l	MPEP 609;	draw line thr	rough citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.								